DEFENCE'S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
DEFENCE'S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS

01.07.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

_________________________________________________________________

CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

DEFENCE'S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS

Vancouver, BC, Canada, June 28th, 2024 - Defence Therapeutics Inc.
("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian
biopharmaceutical company developing novel immune-oncology vaccines and drug
delivery technologies, is please to announce that Defence's Accum-002TM
("AccuTOX®") has different mode of actions: AccuTOX® is working as a tumor
killing molecule and as an immune booster. AccuTOX® mode of action
synergizes with the activity of Immune Checkpoint Inhibitors ("ICI") and the
immune system itself.


Immune Checkpoint Inhibitors produces promising therapeutic effects in
treatments of solid tumors. However, their overall response rate is still
very low for a few patients suffering of solid tumors. For example, melanoma
patient is one population group having the best response with only 20% of
patients having a complete or partial response to ICI treatment. To explain
the intrinsic resistant of those majority of patients to the ICI treatment,
the scientific community discovered that those tumors have a cold tumor
environment which block the patient immune system to recognize and attack
the cancer cells. This cold environment is translated in part by a low level
of immune infiltrating cell inside the tumor and by decreasing the potential
of the immune system to recognize tumor as a non healthy tissue and to
promote the attack and destruction of tumor cells.

The scientific and medical community is seeking solutions to this intrinsic
resistance by transforming this cold tumor into hot tumor by using
combination treatments with ICI. This transformation into hot tumor will
increase tumor vulnerability to ICI treatment and to the immune system
attacks.

Defence Therapeutics team have discovered that the mode of action of AccuTOX®
exploits this tumor vulnerability by inducing immune system recruitment and
increasing the tumor recognition by the immune system, which synergized with
ICI mode of actions. Surprisingly and compared to competitors, AccuTOX®
induces the recruitment and/or the activation of different immune cells and
transforms the cold tumor into very hot tumor which is easily recognized and
attacked by the immune cells. These immune cells are responsible of tumor
regression in context of ICI and other immunotherapy treatments. In other
words, AccuTOX® acts as an intelligent spotlight having specialized lens and
biometric recognition software (facial and fingerprint recognition) for the
immune system to recognize, focus, track and attack cancer tumors inside the
body. AccuTOX® has shown that it induces the death of cancer cells on its
own mode of action and, more importantly, AccuTOX® has the potential to
transform a cold tumor into a hot tumor which the immune system will
recognize, attack, and destroy.

AcccuTOX® has the potential to treat more efficiently the patient who
already has a positive response to ICI treatment and, in fact, AccuTOX® can
increase the patient population eligible to ICI treatment which shall
increase the market of each existing ICI. The Company believes that AccuTOX®
is a strong candidate to enhance and boost the therapeutic value of the ICI
and is open to potential partnerships and collaborations in that regard.

Defence's scientific team has shown in many in vivo preclinical studies that
AccuTOX® significantly increases the efficacy of several ICI (anti-PD1,
anti-CD47, anti-LAG3 and anti-CTLA4) when combined with AccuTOX®, by at
least a factor of 10 folds, to treat different cancer indications. The
PD1/PDL1 (which is the ICI used in most of Defence's AccuTOX®in vivo
preclinical studies) market is projected to grow from USD 36.4 Billion in
2023 to USD 139.7 Billion by 2032, exhibiting a CAGR of 18.3% during the
forecast period of 2023-2032.

https://www.marketresearchfuture.com/reports/pd-l1-inhibitors-market-19205

According to Allied Market Research, the global immune checkpoint inhibitors
market was valued at USD $40.1 billion in 2022, and is projected to reach
USD $189.4 billion by 2032, growing at a CAGR of 16.8% from 2023 to 2032.
The primary driver fueling the immune checkpoint inhibitors market is the
rising global prevalence of cancer.

https://www.alliedmarketresearch.com/immune-check-point-inhibitors-market

About Defence:

Defence Therapeutics is a publicly-traded clinical-stage biotechnology
company working on engineering the next generation vaccines and ADC products
using its proprietary platform. The core of Defence Therapeutics platform is
the ACCUM® technology, which enables precision delivery of vaccine antigens
or ADCs inside target cells and favoring their processing and activities. As
a result, increased efficacy and potency can be reached against catastrophic
illness such as cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking
statements". All statements in this release, other than statements of
historical facts, that address events or developments that the Company
expects to occur, are forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not
always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and similar
expressions, or that events or conditions "will", "would", "may", "could" or
"should" occur. Although the Company believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that
could cause the actual results to differ materially from those in
forward-looking statements include regulatory actions, market prices, and
continued availability of capital and financing, and general economic,
market or business conditions. Investors are cautioned that any such
statements are not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on the
beliefs, estimates and opinions of the Company's management on the date the
statements are made. Except as required by applicable securities laws, the
Company undertakes no obligation to update these forward-looking statements
in the event that management's beliefs, estimates or opinions, or other
factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or accuracy of
this release.


---------------------------------------------------------------------------

01.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Defence Therapeutics Inc.
                   1680 - 200 Burrard St
                   V6C3L6 Vancouver
                   Canada
   E-mail:         info@defencetherapeutics.com
   Internet:       https://defencetherapeutics.com
   ISIN:           CA24463V1013
   WKN:            A3CN14
   Listed:         Regulated Unofficial Market in Frankfurt, Stuttgart;
                   Toronto
   EQS News ID:    1936259

End of News EQS News Service
---------------------------------------------------------------------------

1936259 01.07.2024 CET/CEST